The Committee discusses and makes recommendations on the safety and effectiveness of GSK‘s Biologics License Application (BLA) 125775 (STN 125775/o) for active immunization for the prevention of LRTD caused by respiratory syncytial virus RSV-A and RSV-B subtypes in adults 60 years of age and older in a virtual meeting to be held on March 1 at 8 am. Webcast Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on GSK: